Monographie - Filgrastim - Stabilis 4.0

Siste oppdatering :
19/11/2024

Forskjellig

Filgrastim

Injeksjon

Oppløsningsstabilitet

Stabilitet i blandinger

Faktorer som påvirker stabiliteten

Kompatibilitet

Administrasjonsmåte

Referanser

pdf

Handelsnavn

Handelsnavn

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Accofil	Belgia, Storbritannia, Tyskland
Biocilin	Mexico
Duperan	Chile
Filgen	Argentina
Foltran	Chile
Granulokine	Hellas, Italia
Hebervital	Colombia
Inmunef	Colombia
Leucosos	Colombia
Lioplim	Chile
Neupogen	Belgia, Danmark, Finland, Frankrike, Kroatia, Nederland, Polen, Portugal, Slovenia, Spania, Storbritannia, Sveits, Sverige, Sør-Afrika, Tyrkia, USA, Østerrike
Neutromax	Argentina
Neutropine	Argentina
Nivestim	Belgia, Frankrike, Nederland, Norge, Storbritannia, Tyskland
Ratiograstim	Storbritannia, Sverige, Tyskland, Østerrike
Tevagrastim	Nederland, Norge, Storbritannia, Sveits, Sverige, Tyskland

Referanser

Injeksjon

Referanser : Filgrastim

	Type	publikasjon
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	Journal	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
2269	Journal	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3128	Labratorium	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3249	Journal	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3256	Journal	Burnett B, Radic I. Stability of Hospira filgrastim following changes to thermal and photic storage conditions. EJHP 2011 ; 17, 5: 49-56.
3474	Labratorium	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3618	Labratorium	Filgrastim (Neupogen®) - Summary of Product Characteristics Amgen 2014
3828	plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4380	Labratorium	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4471	Labratorium	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019
4521	Journal	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4650	Labratorium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

Mentions Légales